Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ecco-jcc/jjac116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term efficacy of therapeutic drug monitoring-guided optimization of ustekinumab maintenance therapy for Crohn's disease patients.
Sci Rep
July 2025
Department of Gastroenterology, Renmin Hospital of Wuhan University, 99 Zhangzhidong Road, Wuhan, 430060, Hubei, China.
Long-term remission in Crohn's disease (CD) remains challenging. While ustekinumab effectively induces remission, strategies to enhance its maintenance efficacy are urgently needed. This study evaluated therapeutic drug monitoring (TDM)-guided ustekinumab optimization for sustained CD management.
View Article and Find Full Text PDFUstekinumab-Induced Vasculitis in a Patient With Crohn's Disease.
ACG Case Rep J
March 2025
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Immunoglobulin A vasculitis (IgAV) is an immune-mediated disorder that commonly involves dermatologic, musculoskeletal, renal, and gastrointestinal systems. Drug-induced cases of IgAV are rare and sparsely documented in the literature. We report a case of a patient with Crohn's disease who developed a tender, palpable purpuric rash on the torso and extremities 3 weeks after receiving a dose of ustekinumab.
View Article and Find Full Text PDFPsoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies.
Therap Adv Gastroenterol
November 2024
IBD Centre, Gastroenterology Unit, Rho Hospital, ASST Rhodense, Rho, Italy.
Inflammatory bowel diseases (IBD) and psoriasis are chronic inflammatory conditions belonging to the heterogeneous group of immune-mediated inflammatory diseases (IMIDs). A significant bidirectional link between these two entities has been observed, conditioning an increased risk of IBD in patients with psoriasis and vice-versa. Biological therapies used for IBD may lead to the occurrence of psoriasis as a "paradoxical reaction.
View Article and Find Full Text PDFNon-Infectious Pneumonitis and Acute Respiratory Distress Syndrome in a Patient on Ustekinumab Treatment: Case Report and Literature Review.
Life (Basel)
March 2024
Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Ustekinumab is a monoclonal antibody targeting the p40 subunit of IL-12 and IL-23, approved for treating psoriasis, psoriatic arthritis, and inflammatory bowel disease. Despite a remarkable success in treating chronic inflammatory conditions and a generally favorable safety profile, its role in inducing rare adverse events, such as interstitial pneumonia and acute respiratory distress syndrome (ARDS), remains largely uncharted. We report a case of a 66-year-old male patient treated with Ustekinumab for severe psoriasis who, after almost two years of treatment, developed dyspnea, asthenia, and fever progressing to non-infectious pneumonia and ARDS leading to ICU admission.
View Article and Find Full Text PDFHypersplenism and thrombocytopenia after exposure to ustekinumab in a patient with Crohn's disease.
Arab J Gastroenterol
November 2022
Department of Medicine, College of Medicine, King Khaled University Hospital, Riyadh 12372, Saudi Arabia. Electronic address:
Crohn's disease can be characterized as a chronic inflammatory state causing various clinical presentations and long-term risks that should be considered when determining the optimal therapeutic strategy. To date, while a few case reports have been available regarding ustekinumab-induced thrombocytopenia, none are available regarding hypersplenism. We describe a 33-year-old woman who developed only Ileocolonic Crohn's disease on ustekinumab due to failure of anti-TNF with septic shock and thrombocytopenia.
View Article and Find Full Text PDF